475 related articles for article (PubMed ID: 24565969)
1. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.
Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H
Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
[TBL] [Abstract][Full Text] [Related]
3. Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
Qin M; Wang T; Xu B; Ma Z; Jiang N; Xie H; Gong P; Zhao Y
Eur J Med Chem; 2015 Nov; 104():115-26. PubMed ID: 26451770
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
Chang S; Zhang L; Xu S; Luo J; Lu X; Zhang Z; Xu T; Liu Y; Tu Z; Xu Y; Ren X; Geng M; Ding J; Pei D; Ding K
J Med Chem; 2012 Mar; 55(6):2711-23. PubMed ID: 22339342
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Potent Antiproliferative Agents Targeting EGFR Tyrosine Kinase Based on the Pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine Scaffold.
Aziz YM; Said MM; El Shihawy HA; Tolba MF; Abouzid KA
Chem Pharm Bull (Tokyo); 2015; 63(12):1015-28. PubMed ID: 26633023
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
Xiao Q; Qu R; Gao D; Yan Q; Tong L; Zhang W; Ding J; Xie H; Li Y
Bioorg Med Chem; 2016 Jun; 24(12):2673-80. PubMed ID: 27131639
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
Li J; An B; Song X; Zhang Q; Chen C; Wei S; Fan R; Li X; Zou Y
Eur J Med Chem; 2021 Feb; 212():113019. PubMed ID: 33429247
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties.
Xu S; Xu T; Zhang L; Zhang Z; Luo J; Liu Y; Lu X; Tu Z; Ren X; Ding K
J Med Chem; 2013 Nov; 56(21):8803-13. PubMed ID: 24124898
[TBL] [Abstract][Full Text] [Related]
10. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation.
Yan Q; Chen Y; Tang B; Xiao Q; Qu R; Tong L; Liu J; Ding J; Chen Y; Ding N; Tan W; Xie H; Li Y
Eur J Med Chem; 2018 May; 152():298-306. PubMed ID: 29730192
[TBL] [Abstract][Full Text] [Related]
12. Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors.
Milik SN; Abdel-Aziz AK; Lasheen DS; Serya RAT; Minucci S; Abouzid KAM
Eur J Med Chem; 2018 Jul; 155():316-336. PubMed ID: 29902719
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold.
Zhang H; Wang J; Zhao HY; Yang XY; Lei H; Xin M; Cao YX; Zhang SQ
Bioorg Med Chem; 2018 Jul; 26(12):3619-3633. PubMed ID: 29853340
[TBL] [Abstract][Full Text] [Related]
14. Design and Synthesis of 4-Anilinothieno[2,3-d]pyrimidine-Based Compounds as Dual EGFR/HER-2 Inhibitors.
Abd El Hadi SR; Lasheen DS; Hassan MA; Abouzid KA
Arch Pharm (Weinheim); 2016 Nov; 349(11):827-847. PubMed ID: 27734525
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
Lin R; Johnson SG; Connolly PJ; Wetter SK; Binnun E; Hughes TV; Murray WV; Pandey NB; Moreno-Mazza SJ; Adams M; Fuentes-Pesquera AR; Middleton SA
Bioorg Med Chem Lett; 2009 Apr; 19(8):2333-7. PubMed ID: 19286381
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
Han C; Huang Z; Zheng C; Wan L; Lai Y; Peng S; Ding K; Ji H; Zhang Y
Eur J Med Chem; 2013 Aug; 66():82-90. PubMed ID: 23792318
[TBL] [Abstract][Full Text] [Related]
18. 2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFR(L⁸⁵⁸R/T⁷⁹⁰M).
Chan S; Han K; Qu R; Tong L; Li Y; Zhang Z; Cheng H; Lu X; Patterson A; Smaill J; Ren X; Ding J; Xie H; Ding K
Bioorg Med Chem Lett; 2015 Oct; 25(19):4277-81. PubMed ID: 26259806
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.
Zhang Y; Lv H; Luo L; Xu Y; Pan Y; Wang Y; Lin H; Xiong J; Guo P; Zhang J; Li X; Ye F
Eur J Med Chem; 2018 Sep; 157():1300-1325. PubMed ID: 30195240
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
Song Z; Huang S; Yu H; Jiang Y; Wang C; Meng Q; Shu X; Sun H; Liu K; Li Y; Ma X
Eur J Med Chem; 2017 Jun; 133():329-339. PubMed ID: 28395219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
